Trial Profile
An intra-subject, randomized, double blind, crossover study comparing immediate-release oral LD (IR-LD) and L-dopa/carbidopa intestinal gel (LCIG) over cognition and mood in non-demented advanced Parkinson's disease (PD) patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- 26 May 2020 Results presented at the 6th Congress of the European Academy of Neurology
- 15 Feb 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 01 Dec 2015 New trial record